Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Smiling” Bob?

This article was originally published in The Tan Sheet

Executive Summary

Enzyte marketer Berkeley Premium Nutraceuticals "has been able to reduce customer complaints by 90% and has held a steady average of less than two per week" during the past 24 months, the firm announces Sept. 6. The company has spent "well over $20 mil." to buy equipment and create the necessary departments to ensure total industry compliance, and has confirmed through four separate third-party surveys that customers are very satisfied with Berkeley brands. The firm recently paid $2.5 mil. in settlement and restitution costs in a consent agreement that arose from thousands of consumer complaints in six states (1"The Tan Sheet" March 6, 2006, p. 8)...

You may also be interested in...

Enzyte Marketer Berkeley Settles Complaints For $2.5 Mil.

Berkeley Premium Nutraceuticals will pay $2.5 mil. in legal costs and restitution in accordance with a consent agreement, the firm announced March 1

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts